Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Europa Stream

 

Fresenius half-year results get lukewarm reception

Investors had a mixed reaction to Fresenius’ half-year results, which saw the firm perform poorly on a group-level, but the core businesses highlighted by the restructuring plan perform well. The company did not confirm rumours of divestments.

HBI 2023: Opportunities in ophthalmology

Ophthalmology continues to be a big area of interest for investors, with considerable scope for consolidation. An expert panel including the CEO of Europe's largest chain (Veonet) and the CEO of Latin America's largest player (Opty) discussed opportunities in the sector at HBI 2023.

Aedifica finds buyers for Orpea’s Brussels homes

Belgium-based real estate specialist Aedifica has confirmed the sale of five of its nine Orpea homes, all located in Brussels. The news confirms previous speculation that Belgium was next on the French nursing home’s divestment list from a €1.2bn chunk of its real estate portfolio.

Dutch care staff awarded pay hikes to compete with temp agencies

In a bid to compete with temporary agencies, elderly care staff in the Netherlands as set to receive salary hikes of 5% this October - with another 5% increase again in 2024. HBI speaks to one Dutch sector expert to understand the reasoning behind the move and ask if will it have the desired effect.

Max Healthcare appeals Care Hospital decision

Indian hospital group Max Healthcare is appealing a court decision to reject its claim concerning Care Hospital, another Indian hospital group which it tried to acquire, which it made after the latter accepted an alternative offer from US private equity firm Blackstone.

Orpea sells in Austria and the Netherlands

The ongoing sale of significant parts of French nursing home operator Orpea’s €1.2bn real estate portfolio has expanded to Austria and the Netherlands. As newly released H1 figures show low occupancy rates in France, HBI speaks to three market experts to gauge the current state of affairs for the French giant looking to bounce back from its recent troubled history.

Are fertility add-ons a bad idea?

In a successful fertility market, add-ons remain a controversial subject. HBI speaks to two experts with differing opinions to find out why.

Find Us